Increased soluble APPα, abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from down syndrome patients

Alzheimer Disease and Associated Disorders

Volumn 24, Issue 1, 2010, Pages 96-100

  Conti, Elisa ^a,b   Galimberti, Gloria ^a,b   Piazza, Fabrizio ^a   Raggi, Maria Elisabetta ^b   Ferrarese, Carlo ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Abeta 1 42; Anti Abeta 1 42 antibodies; Biomarker; Down syndrome; SAPPa

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AUTOANTIBODY; PEPTIDE FRAGMENT;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; GENOTYPE; HUMAN; MALE; MENTAL DEFICIENCY; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY;

ADULT; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AUTOANTIBODIES; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS;

EID: 77949470143     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181aba63a     Document Type: Article

References (30)

1. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol. 1989;46:849-853.
2. Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease. Behav Genet. 2006;36:405-415.
3. Rumble B, Retallack R, Hilbich C, et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med. 1989;320:1446-1452.
4. Wisniewski H, Wegiel J, Popovitch E. Age-associated development of diffuse and thioflavin-S-positive plaques in Down syndrome. Dev Brain Dysfunct. 1995;7:330-339.
5. Iwatsubo T, Mann DM, Odaka A, et al. Amyloid beta protein (A beta) deposition: a beta 42(43) precedes Abeta 40 in Down syndrome. Ann Neurol. 1995;37:294-299.
6. Schupf N. Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry. 2002;180:405-410.
7. Wisniewski T, Morelli L, Wegiel J, et al. The influence of apolipoprotein E isotypes on Alzheimer's disease pathology in 40 cases of Down's syndrome. Ann Neurol. 1995;37:136-138.
8. Cavani S, Tamaoka A, Moretti A, et al. Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet. 2000;95:224-228.
9. Mehta PD, Mehta SP, Fedor B, et al. Plasma amyloid beta protein 1-42 levels are increased in old Down syndrome but not in young Down syndrome. Neurosci Lett. 2003;342:155-158.
10. Mehta PD, Capone G, Jewell A, et al. Increased amyloid beta protein levels in children and adolescents with Down syndrome. J Neurol Sci. 2007;254:22-27.
11. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett. 2001;301:199-203.
12. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001; 57:801-805.
13. Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943-948.
14. Baril L, Nicolas L, Croisile B, et al. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett. 2004; 355:226-230.
15. Brettschneider S, Morgenthaler NG, Teipel SJ, et al. Decreased serum amyloid beta (1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta (1-42) peptide. Biol Psychiatry. 2005;57:813-816.
16. Nath A, Hall E, Tuzova M, et al. Autoantobodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromoleculor Med. 2003;3:29-39.
17. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by amplification and cleavage with HhaI. J Lipid Res. 1990;31:545-548.
18. Cheon MS, Dierssen M, Kim SH, et al. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids. 2008;35:339-343.
19. Rachidi M, Lopes C. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur J Paediatr Neurol. 2008; 12:168-182.
20. Sun X, Tong Y, Qing H, et al. Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. 2006;20:1361-1368.
21. Cai H, Wang Y, McCarthy D, et al. BACE1 is the major betasecretase for generation of Abeta peptides by neurons. Nat Neurosci. 2001;4:233-234.
22. Russo C, Schettini G, Saido TC, et al. Presenilin-1 mutations in Alzheimer's disease. Nature. 2000;405:531-532.
23. Carson JA, Turner AJ. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem. 2002;81:1-8.
24. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloidbeta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci. 2003;23:8867-8871.
25. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916-919.
26. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
27. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408: 979-982.
28. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med. 1996;2:93-95.
29. Ma QL, Lim GP, Harris-White ME, et al. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res. 2006;83:374-384.
30. Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev. 2008;7: 415-420.